Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivoSim LabsFRA:4OR 33 Cash-to-Debt is 11.23 as of Mar. 2026, which is 100% below its 10-year median of 5,006.57. GuruFocus rates FRA:4OR with a GF Score™ of 33/100 and a GF Value™ of €17.26. The stock has 6 warning signs investors should review. Among 1,399 Biotechnology companies, VivoSim Labs ranks better than 56.18% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. VivoSim Labs's cash to debt ratio for the quarter that ended in Mar. 2026 was 11.23.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, VivoSim Labscould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for VivoSim Labs's Cash-to-Debt or its related term are showing as below:
FRA:4OR'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.08 Med: 5006.57 Max: No Debt
Current: 11.24
During the past 13 years, VivoSim Labs's highest Cash to Debt Ratio was No Debt. The lowest was 2.08. And the median was 5006.57.
FRA:4OR's Cash-to-Debt is ranked better than 56.18% of 1399
companies
in the Biotechnology industry
Industry Median: 6.56
vs FRA:4OR: 11.24
VivoSim Labs (FRA:4OR) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
VivoSim Labs Cash-to-Debt Related Terms
VivoSim Labs Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for VivoSim Labs's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:4OR vs MTNB, HEPA, CLSDQ: Cash-to-Debt Comparison
For the Biotechnology subindustry, VivoSim Labs's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
VivoSim Labs Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, VivoSim Labs's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where VivoSim Labs's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VivoSim Labs (FRA:4OR) has a Cash-to-Debt of 11.23 as of Mar. 2026. This is 100% below median its historical median of 5,006.57. Over the past decade, VivoSim Labs' Cash-to-Debt has ranged from 2.08 to 10,000.00. According to the industry distribution chart, VivoSim Labs ranks #613 out of 1399 companies in the Biotechnology industry, placing it in the top 43.8%.
Is VivoSim Labs' Cash-to-Debt too high?
VivoSim Labs' current Cash-to-Debt of 11.23 is 100% below median its 10-year median of 5,006.57. Over the past 10 years, this metric has ranged from a low of 2.08 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.56. VivoSim Labs' value of 11.23 is 71.2% above this industry median. Based on the distribution chart, VivoSim Labs ranks #613 out of 1399 companies in the Biotechnology industry, which is above the industry midpoint. Overall, VivoSim Labs has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does VivoSim Labs' Cash-to-Debt compare to MTNB and HEPA?
According to the Biotechnology industry distribution chart, VivoSim Labs ranks #613 out of 1399 companies for Cash-to-Debt. This puts VivoSim Labs in the upper half of its industry. The industry median Cash-to-Debt is 6.56. VivoSim Labs' value of 11.23 is 71.2% above this benchmark. Historically, VivoSim Labs' own Cash-to-Debt has ranged from 2.08 to 10,000.00 over the past decade. While the company's 10-year median is 5,006.57 vs. the industry median of 6.56, VivoSim Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.56, based on 1,399 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. VivoSim Labs's current Cash-to-Debt of 11.23 is 71.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. VivoSim Labs's current Cash-to-Debt is 11.23, which is 100% below median its own 10-year median of 5,006.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is VivoSim Labs stock overvalued right now?
VivoSim Labs (FRA:4OR) has a current Cash-to-Debt of 11.23. The stock's GF Value™ is €17.26, compared to a current price of €3.49 — trading 79.8% below its estimated fair value. The current Cash-to-Debt is 11.23, which is 100% below median its 10-year median of 5,006.57 and 71.2% above the Biotechnology industry median of 6.56. VivoSim Labs' overall GF Score™ is 33/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For VivoSim Labs (FRA:4OR), the current Cash-to-Debt is 11.23 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is VivoSim Labs (FRA:4OR) Overvalued in 2026?
Based on GuruFocus' analysis, VivoSim Labs stock appears to be undervalued.
The current stock price of €3.49 is trading 79.8% below its estimated GF Value™ of €17.26.
Key valuation signals for FRA:4OR:
Cash-to-Debt: 11.23 (100% below median its 10-year median of 5,006.57)
GF Value™: €17.26 vs. price of €3.49 (79.8% below fair value)
Industry Position: 71.2% above the Biotechnology median (#613 of 1399)
No single metric tells the full story. See the FRA:4OR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
33GF Score
Get the complete analysis for FRA:4OR
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4OR has been successfully added to your 
